Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun;8(11):728.
doi: 10.21037/atm-2020-95.

Is there hope in improving 5-year overall survival?-review of 5-year overall survival data from KEYNOTE-001

Wisdom Akingbemi  1 , Edward Garon  1
Affiliations
Comment

Is there hope in improving 5-year overall survival?-review of 5-year overall survival data from KEYNOTE-001

Wisdom Akingbemi et al. Ann Transl Med. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-2020-95). EG reports personal fees from Dracen Pharmaceuticals, grants and personal fees from EMD Serono, personal fees from GSK, grants and personal fees from Novartis, grants from AstraZeneca, grants from Genentech, grants from Bristol-Myers Squibb, grants from Merck, grants from Eli Lilly, grants from Iovance, grants from Neon, grants from Dynavax, grants from Mirati, outside the submitted work. WA has no conflicts of interest to declare.

Comment on

References

    1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 2015;372:2018-28. 10.1056/NEJMoa1501824 - DOI - PubMed
    1. Garon EB, Hellmann MD, Rizvi NA, et al. Five Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 2019;37:2518-27. 10.1200/JCO.19.00934 - DOI - PMC - PubMed
    1. Cohen AY, Kian W, Roisman LC, et al. Are we facing a cure in lung cancer? – KEYNOTE-001 insights. Ann Transl Med 2019;7:S215. 10.21037/atm.2019.08.87 - DOI - PMC - PubMed
    1. Bironzo P, Passiglia F, Novello S. Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure? Ann Transl Med 2019;7:S212. 10.21037/atm.2019.08.91 - DOI - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol 2019;5:1411-20. 10.1001/jamaoncol.2019.2187 - DOI - PMC - PubMed